We have developed one of the richest and most diversified innovative antibody drug pipelines in China covering over 20 drug development programs, including 12 antibodies in clinical-stage development, six bi-specific antibodies (two at clinical stage), and four antibodies with IND approvals from the FDA. Since 2017, we have initiated 22 clinical trials for our innovative drug candidates.

Akeso pipeline landscape
Diversified and robust pipeline